Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin + Metformin 50 mg/1000 mg vs Janumet 50 mg/1000 mg under fed conditions in healthy Thai volunteers
TCTR20201119001Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin, sitagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
sitagliptin + metforminsitagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20201119001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201119001.